Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1α

Transplantation

Volumn 83, Issue 10, 2007, Pages 1371-1379

  Imamura, Ryoich ^a   Moriyama, Toshiki ^b   Isaka, Yoshitaka ^a   Namba, Yukiomi ^a   Ichimaru, Naotsugu ^a   Takahara, Shiro ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Cell proliferation; Erythropoietin; Hypoxia inducible factor 1 ; Ischemia reperfusion injury; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PIMONIDAZOLE; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MALE; MOLECULAR PROBE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPERFUSION INJURY; SPRAGUE DAWLEY RAT; TEMPERATURE; UMBILICAL CORD; VASCULAR ENDOTHELIUM;

ANOXIA; CELL DIVISION; CELL LINE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KIDNEY; REPERFUSION INJURY; RNA, MESSENGER; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249110579     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000264200.38926.70     Document Type: Article

References (35)

1. Gueler F, Gwinner W, Schwarz A, Haller H. Long-term effects of acute ischemia and reperfusion injury. Kidney Int 2004; 66: 523.
2. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: Etiology, management and long-term significance. J Urol 1996; 155: 1831.
3. Krantz SB. Erythropoietin. Blood 1991; 77: 419.
4. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998; 95: 4635.
5. Alafaci C, Salpietro F, Grasso G, et al. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000; 406: 219.
6. Chong ZZ, Kang JQ, Maiese K. Erythropoietin: Cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 141.
7. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004; 11 Suppl 1: S37.
8. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412: 641.
9. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 2002; 99: 2258.
10. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000; 97: 10526.
11. Eid T, Brines M. Recombinant human erythropoietin for neuroprotection: what is the evidence? Clin Breast Cancer 2002; 3 (Suppl 3): S109.
12. Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 2073.
13. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003; 308: 990.
14. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999.
15. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004; 44: 473.
16. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004; 101: 14907.
17. Xu B, Dong GH, Liu H, et al. Recombinant human erythropoietin pre-treatment attenuates myocardial infarct size: A possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci 2005; 35: 161.
18. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005; 100: 397.
19. Schwartzenberg S, Ben-Shoshan J, Keren G, George J. The role of erythropoietin in myocardial protection: potential mechanisms and applications. Expert Rev Cardiovasc Ther 2006; 4: 41.
20. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. Faseb J 2003; 17: 1754.
21. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115.
22. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266: F360.
23. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001; 16: 932.
24. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348.
25. Zagorska A, Dulak J. HIF-1: The knowns and unknowns of hypoxia sensing. Acta Biochim Pol 2004; 51: 563.
26. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004; 43: 649.
27. Csete M, Rodriguez L, Wilcox M, Chadalavada S. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci Lett 2004; 359: 124.
28. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996; 88: 1576.
29. Rossert J, Eckardt KU. Erythropoietin receptors: Their role beyond erythropoiesis. Nephrol Dial Transplant 2005; 20: 1025.
30. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808.
31. Zhang Q, Oh CK, Messadi DV, et al. Hypoxia-induced HIF-1 alpha accumulation is augmented in a co-culture of keloid fibroblasts and human mast cells: involvement of ERK1/2 and PI-3K/Akt. Exp Cell Res 2006; 312: 145.
32. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995.
33. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280: 22473.
34. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 27975.
35. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085.